Presentation is loading. Please wait.

Presentation is loading. Please wait.

In-Jin Jang M.D., Ph.D. Clinical Pharmacology Unit, Clinical Trial Center Seoul National University Hospital (SNUH) & Seoul National University College.

Similar presentations


Presentation on theme: "In-Jin Jang M.D., Ph.D. Clinical Pharmacology Unit, Clinical Trial Center Seoul National University Hospital (SNUH) & Seoul National University College."— Presentation transcript:

1

2 In-Jin Jang M.D., Ph.D. Clinical Pharmacology Unit, Clinical Trial Center Seoul National University Hospital (SNUH) & Seoul National University College of Medicine Seoul National University Hospital (SNUH) & Seoul National University College of Medicine Experience in Korea on Bridging Studies

3 SNUH-CTC Recent Changes in Korean Regulations for Clinical Trials n n 1999 l l Elimination of compulsory conduction of local clinical trial in Korea as a condition of registration (For the products with < 3yr market experience or, For the products only marketed in the original developing country) n n Introduction of Bridging Study System; Dec n n Bridging study waiver until June 2001 l l Allowance for conducting the multi-national, multi-center trials n n 2002 l l Separation of IND system and NDA system. l l Began to collect user-fee but not providing consultation about the clinical trial designs yet.

4 SNUH-CTC n Track for “marketing approval without domestic/Korean bridging data”;  8 drugs l 1 for life-threatening condition, l 4 orphan drugs, l 1 diagnostic, l 1 topical drug, l 1 antibiotic without domestic/Korean clinical data  on the basis of ethnic insensitivity and in vitro microbiological sensitivity test of domestic clinical isolates l 2 failed to register without domestic bridging data  Insulin analogue and one more endocrine drug Bridging Data Generation : Experiences in Korea (1)

5 SNUH-CTC n Track for single pharmacokinetic study for bridging data generation;  11 drugs l Three products were approved with single Korean pharmacokinetic clinical trial data.  Actos, Avandia, Gastrointestinal (GI) drug  GI drug study was done in Koreans living in an other country l Three sponsors finished PK studies  ED, IBS, antimuscarinic l More than 5 sponsors are planning to do PK based bridging data generation  BPH/alopecia, diuretic, vascular, antihyperlipidemic, hormonal agent Bridging Data Generation : Experiences in Korea (2)

6 SNUH-CTC n Track for phase 3 clinical study for bridging data ;  11 drugs, (12 indications) l None approved yet l Open trial: 3, Blinded trial: 9 l Placebo control: 2, Active control: 7 l Sample size: 30 (open) ~ 284 (142 x 2) l Therapeutic class  Analgesics (1), Antibiotic (1), Erectile dysfunction (1), Endocrine (3), Glaucoma (1), Antipsychotic (1), Respiratory (1), Rheumatic (2) Bridging Data Generation : Experiences in Korea (3)

7 SNUH-CTC n Multi-national phase 2/3 clinical study for bridging data ;  19 drugs, (23 trials) l None approved yet l Open trial: 7, Blinded: 12 l Placebo control: 8, Active control: 12 l Sample size: 16, 30/630, 98, 20/700, etc. l Therapeutic class  Antibiotic (3), Anticancer (7), Antifungal (1), Antihypertensive (2), Antiviral (2), ED (1), Dementia (1), Gastrointestinal (2), Osteoporosis (2), Thrombolytic (1), CNS (1) Bridging Data Generation : Experiences in Korea (4)

8 Clinical Trial Center / Clinical Pharmacology Unit Seoul National University Hospital (SNUH) Pharmacokinetics of XX prolonged release capsules in Japanese, Caucasian and Korean healthy volunteers, with a tolerability assessment in the Japanese subjects. A multiple-dose, placebo-controlled sequential dose-escalation study

9 SNUH-CTC Study Summary n Objectives: show similarity in steady state AUC for the active moiety (sum of the unbound parent drug and metabolite1) between Japanese versus Caucasians and Japanese versus Korean subjects n Study design: l Parallel group l Age/weight matching of the Caucasian and Korean groups to Japanese l Single-dose and 5-day multiple dose administration n Dosage and subjects Treatment definition JapaneseCaucasianKorean ActivePlaceboActiveActive x mg x mg x mg

10 SNUH-CTC SubstancePeriodRatio 90 C.I. Lower bound 90 C.I. Upper bound Active (M1+P)Day 1 incl. outliers Metabolite1Day Parent drugDay 1 incl. outliers SubstancePeriodRatio 90 C.I. Lower bound 90 C.I. Upper bound Active (M1+P)Day 7 incl. outliers Metabolite1Day 7 incl. outliers Parent drugDay 7 incl. outliers Point estimate and 90 % C.I. for AUC 0-  ratios in Japanese/Caucasian

11 SNUH-CTC SubstancePeriodRatio 90 C.I. Lower bound 90 C.I. Upper bound Active (M1+P)Day 1 incl. outliers Metabolite1Day 1 incl. outliers Parent drugDay 1 incl. outliers SubstancePeriodRatio 90 C.I. Lower bound 90 C.I. Upper bound Active (M1+P)Day 7 incl. outliers MetaboliteDay 7 incl. outliers Parent drugDay 7 incl. outliers Point estimate and 90 % C.I. for AUC 0-24 ratios in Japanese/Korean

12 In-Jin Jang M.D., Ph.D. Clinical Pharmacology Unit /Clinical Trial Center Seoul National University Hospital (SNUH) Phase I Study of YY, Placebo-controlled, Double- blind, Group-comparison, Dose-escalation study to Investigate Safety, Tolerability, and Pharmacokinetics after Single Oral Dosing of 5mg, 10mg and 20mg in Healthy Subjects

13 SNUH-CTC Study Summary n Study design l Placebo-controlled, single ascending dose, parallel group l Double-blind, randomized study n Dosage and subjects StepsDosage Number of Subject Drugs 1 5 mg 8 Active, 5mg tablet 2 Placebo, 5mg tablet 2 10 mg 8 Active, 10mg tablet 2 Placebo, 10mg tablet 3 20 mg 8 Active, 20mg tablet 2 Placebo, 20mg tablet

14 SNUH-CTC Pharmacokinetics Plasma concentration profiles of Study Drug after single oral dosing of 5, 10 and 20 mg under fasting condition

15 SNUH-CTC Korean vs. Caucasian Study Number 000 Race KoreanCaucasian (n=8) (n=24) Dose (mg) T max (h) b 0.5 (0.5~0.75) 0.5 (0.5~0.75) 0.5 (0.5~1.0) (0.50~1.5) (0.48~1.5) C max ( ㎍ /L) 9.70/ / / / /1.52 AUC ( ㎍ *h/L) 17.92/ / / / /1.53 T 1/2 (h)3.49/ / / / /1.36 Vz/F (L/kg)21.54/ / / / /1.50 CL/F (L/h)278.9/ / / / /1.53

16 SNUH-CTC Korean vs. Caucasian

17 Evaluation of Safety and Pharmacokinetics of Single Dose of Rosiglitazone in Healthy Korean Volunteers In-Jin Jang, MD, PhD Clinical Trial Center / Clinical Pharmacology Unit Seoul National University Hospital (SNUH)

18 SNUH-CTC

19

20

21 ACTOS ® PK/PD Modeling and Simulation for Bridging In-Jin Jang MD PhD Clinical Trial Center/Clinical Pharmacology Unit Seoul National University Hospital KFDA CPAC

22 SNUH-CTC DosePioglitazonePlacebo 15 mg 30 mg 45 mg 6 Male + 3 Female 2 Male + 1 Female A Single Dose, Dose-Escalation Study to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of Pioglitazone in Healthy Korean Subjects

23 SNUH-CTC Direct AUC Comparison Koreans vs. Western

24 SNUH-CTC Predicted Glucose Response - AUC Relationships in Korean Populations Glucose -AUC relationships from global data supports 15 and 30 mg as efficacious doses in Koreans

25 SNUH-CTC Parameter Estimate StdErr %SE THETA #1 KA THETA #2 CL THETA #3 V THETA #4 orig OMEGA #1 CL SIGMA # $PK PJ=0 IF(PROJ.EQ ) PJ=1 KA=THETA(1) TVCL=THETA(2)*(1 + PJ*THETA(4)) CL =TVCL*EXP(ETA(1)) TVV =THETA(3) V =TVV S2 =V $ERROR IPRED = F W=IPRED IRES=DV-IPRED IWRES=IRES/W Y = F*EXP(ERR(1)) Korean & US Combined PK by NONMEM

26 SNUH-CTC Simulation Plan Korean Study DoseAUC US Study DoseAUCResponse Emax Model Response Actual US Results Comparison

27 SNUH-CTC Trial Simulation Platform 5 dose group (0, 7.5, 15, 30, 45 mg, N=500), 300 replications

28 SNUH-CTC Distribution of 300 Mean Changes in FBG (mM) of Korean 15mg Group US 30mg Group Mean Effect = percentile Median =

29 SNUH-CTC Distribution of 300 Mean Changes in FBG (mM) of Korean 30 mg Group US actual trial 45mg Group Mean Effect = percentile Median = -3.04

30 SNUH-CTC Predicted CFBG Dose For Korean patients (mg/day) Dose For US patients (mg/day) US Korean Predicted Mean Change From Baseline Overlapping of Effect Range

31 SNUH-CTCConclusion n n Bridging concept is actively applied but regulatory experience is still limited in Korea. n n No official bridging study has been requested by Korean regulatory body until now. n n Differences in pharmacokinetics among ethnic groups (even between Japanese and Korean) were frequently observed. n n Mechanisms and clinical implications of such PK differences should be explored and reflected in local label on scientific bases. n n Need sponsors’ cooperation and changes in attitude (strategy ?) toward more scientific and informative clinical development in Korea.


Download ppt "In-Jin Jang M.D., Ph.D. Clinical Pharmacology Unit, Clinical Trial Center Seoul National University Hospital (SNUH) & Seoul National University College."

Similar presentations


Ads by Google